1
|
Mahmoudian J, Ghods R, Nazari M, Jeddi-Tehrani M, Ghahremani MH, Ostad SN, Zarnani AH. Expression profiling of plac1 in murine cancer cell lines. Exp Oncol 2019; 41:7-13. [PMID: 30932401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Placenta-specific 1 (PLAC1) is among recently-discovered placental antigens which exerts fundamental role in placental function and development. Increasing body of literature shows that PLAC1 is frequently activated and expressed in a wide variety of human cancers and promote cancer progression. However, no data is available regarding the expression of mouse orthologue, plac1, in murine cancer cell lines. Materials and Methods: We investigated the expression of plac1 in a series of murine cell lines from different histological origins, mammary carcinoma (4T1), melanoma (B16F10), colorectal carcinoma (CT26), renal carcinoma (Renca), glioma (GL26), B-cell lymphoma (A20 and BCL1) and also two fibroblast cell lines (NIH3T3 and L929), using RT-PCR, Western blotting and flow cytometry. Results: Our data demonstrated that plac1 transcript and plac1 protein were expressed in all examined cell lines, as judged by RT-PCR and Western blot, respectively. The molecular weight of mouse plac1 was experimentally observed to be approximately 24 kD. Flow cytometric analysis showed surface expression of plac1 in aforesaid cell lines ranging from 2% to 42.5%. Conclusion: Based on the ubiquitous expression of plac1, the investigated cancer cell lines or immortalized cell lines can be used to examine the role of plac1 in the process of immortalization.
Collapse
Affiliation(s)
- J Mahmoudian
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, TUMS, Tehran 19615-1177, Iran
- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran 19615-1177, Iran
| | - R Ghods
- Oncopathology Research Center, Iran University of Medical Sciences, IUMS, Tehran 14496-14535, Iran
- Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, IUMS, Tehran 14496-14535, Iran
| | - M Nazari
- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran 19615-1177, Iran
| | - M Jeddi-Tehrani
- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran 19615-1177, Iran
| | - M H Ghahremani
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, TUMS, Tehran 19615-1177, Iran
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155/6451, Iran
| | - S N Ostad
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, TUMS, Tehran 19615-1177, Iran
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155/6451, Iran
| | - A H Zarnani
- Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran 14155/6446, Iran
- Department of Immunology, School of Public Health, Tehran University of Medical Science, Tehran 14155/6446, Iran
- Immunology Research Center, IRC, Iran University of Medical Sciences, Tehran 14155/6446, Iran
| |
Collapse
|